

Crohn's Disease

RO7790121 for the Treatment of Moderate to Severe Active Crohn's Disease

Trial Status Active, not recruiting	Trial Runs In 4 Countries	Trial Identifier NCT05910528 2023-504265-23-00 GA45392
---	-------------------------------------	---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of RO7790121 (RVT-3101) in adult participants with moderate to severe active Crohn's disease.

Hoffmann-La Roche Sponsor	Phase 2 Phase
-------------------------------------	-------------------------

NCT05910528 2023-504265-23-00 GA45392
Trial Identifiers

Eligibility Criteria:

Gender All	Age ≥18 Years & ≤ 75 Years	Healthy Volunteers No
----------------------	--------------------------------------	---------------------------------
